References
- DeVita V T, Canellos G P, Chabner B, Schein P, Hubbard S P, Young R C. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975; 1: 248
- Skarin A T, Rosenthal D S, Moloney W C, Frei E. Combination chemotherapy of advanced non-Hodgkin's lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). Blood 1977; 49: 759
- Jones S E, Grozea P N, Metz E N, Haut A, Stephens R L, Morrison F S, Talley R, Butler J J. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy: a Southwest Oncology Group study. Cancer 1983; 51: 1083
- Coltman C A, Dahlberg S, Jones S E, Miller T P, Dana B W, Weick J K, McKelvey E M, Hartsock R J. Southwest Oncology Group studies in diffuse large cell lymphoma: a subset analysis. Cancer Chemotherapy: Challenges for the Future, K Kimura. Excerpta Medica, Tokyo 1988; 194
- O'Reilly S E, Hoskins P, Klimo P, Connors J M. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991; 2: 17
- Schneider A M, Straus D J, Schluger A E, Lowenthal D A, Koziner B, Lee B J, Wong G, Clarkson B D. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate and some high grade non-Hodgkin's lymphomas. J Clin Oncol 1990; 8: 94
- Weick J K, Dahlberg S, Fisher R I, Dana B, Miller T P, Balcerzak S P, Pierce H I. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: A Southwest Oncology Group study. J Clin Oncol 1991; 9: 748
- Vitolo U, Bertini M, Brusamolino E, Cavallero G B, Comotti B, Gallo E, Ghio R, Levis A, Luxi G, Meneghini V, Novero D, Orsucci L, Rota-Scalabrini D, Tarella C, Todeschini G, Viero P, Barbui T, Bernasconi C, Perona G, Pileri A, Resegotti L. MACOP-B treatment in diffuse large-cell lymphoma: Identification of prognostic groups in an Italian multicenter study. J Clin Oncol 1992; 10: 219
- Fisher R I, DeVita V T, Hubbard S M, Hide D C, Longo D L, Phares J C, Jaffe E S, Wesley R. Randomized trial of Pro MACE-MOPP (day 1, day 8) vs Pro MACE-Cyta BOM in previously untreated, advanced stage, diffuse aggressive lymphomas. Proc Am Soc Clin Oncol 1984; 3: 242a
- Fisher R I, DeVita V T, Hubbard S M, Longo D L, Wesley R, Chabner B A, Young R C. Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of Pro MACE and MOPP chemotherapy. Ann Intern Med 1983; 98: 304
- Miller T P, Dahlberg S, Weick J K, Files J C, Eyre H J, Pendergrass K B, Fisher R I. Unfavorable histologies of non-Hodgkin's lymphoma treated with Pro MACE-Cyta BOM: A groupwide Southwest Oncology Group study. J Clin Oncol 1990; 8: 1951
- Longo D L, DeVita V T, Duffey P L, Wesley M N, Hide D C, Hubbard S M, Gilliom M, Jaffe E S, Cossman J, Fisher R I, Young R C. Superiority of Pro MACE-Cyta BOM over Pro MACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol 1991; 9: 25
- Sertoli M R, Santini G, Chisesi T, Congiu A M, Rubagotti A, Contu A, Salvagno L, Coser P, Porcellini A, Vespignani M, Capnist G, Rossi E, Mangoni L, Fabris P, Vinante O, Tedeschi L, Endrizzi L, Miglio L P, Perrotta A, Rosso R, Damasio E, Rizzoli V. MACOP-B versus Pro MACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group. J Clin Oncol 1994; 12: 1366
- Cooper I A, Wolf M M, Robertson T I, Fox R M, Matthews J P, Stone J M, Ding J C, Dart G, Matthews J, Firkin F C, Lowenthal R M, Ironside P. Randomized comparison of MACOP-B and CHOP in patients with intermediate grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 769
- Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, Glick J H, Coltman C A, Miller T P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Eng J Med 1993; 328: 1002